Regeneron Opens Phase 1 Study of Injectable Obesity Candidate REGN20934
核心洞察
Regeneron Pharmaceuticals has begun a Phase 1 trial of REGN20934 (搜索), an injectable drug candidate for adults with overweight (搜索) or obesity (搜索).
The randomized, double-blind, placebo-controlled study evaluates single ascending doses, focusing on safety, tolerability and pharmacokinetics.
The trial was first submitted on May 11, 2026, and its ClinicalTrials.gov listing was last updated on September 23, 2026, under NCT07594093.
Regeneron Pharmaceuticals is running a Phase 1 study of REGN20934 (搜索), an injectable drug candidate for adults with overweight (搜索) or obesity (搜索), according to the trial's ClinicalTrials.gov listing. The study, titled "A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of REGN20934 in Adult Participants With Overweight or Obesity," is designed to assess safety and early drug behavior in the body.
Trial Design
Participants are randomly assigned to receive REGN20934 (搜索) or placebo. The double-blind design means neither patients nor most study staff know who receives the active drug. The study focuses mainly on safety and pharmacokinetics, describing how the drug moves through the body. The protocol uses single ascending doses, a standard early-stage approach for characterizing a new injectable agent.
The listing was first submitted on May 11, 2026, marking the formal start of the clinical path for the asset, and was last updated on September 23, 2026. Regeneron states that the protocol details and recruitment status are current and that the program is actively managed. Full information is available on the ClinicalTrials.gov portal under NCT07594093.
Positioning in Obesity Drug Development
REGN20934 (搜索) is intended to help manage weight over time if later trials confirm benefit. The Phase 1 program lays groundwork for Regeneron's entry into the obesity (搜索) treatment market, where the company would compete with established obesity drug leaders Novo Nordisk and Eli Lilly. The candidate remains in early-stage testing, and efficacy data from later-phase trials would be needed to establish any weight-management benefit.